Genhouse Bio Announced First Patient First Dose Achieved in Phase I Clinical Trial of GH35


On September 28th 2021, Genhouse Bio, a biotech company focusing on development of next-generation anti-cancer therapeutics, announced today that the first patient has completed first dose in phase I clinical trial of GH35. This is a multi-center, open-label phase I clinical trial to evaluate the safety, tolerability and PK profile of GH35 in patients with KRAS mutated late stage solid tumors. This is the first-in-human clinical trial of Genhouse Bio in China.


GH35 is a KRAS G12C irreversible inhibitor. Both in vivo and in vitro studies have shown that GH35 has very high inhibitory activity and selectivity against KRAS G12C mutant but has no obvious effect on wild type KRAS or other safety-related targets, thus has very low off-target effect. GH35 monotherapy showed significant efficacy against lung cancer, colorectal cancer and pancreatic cancer in CDX/PDX models. Moreover, GH35 has substantial blood-brain barrier penetration, which makes it possible to treat brain-metastasis patients.


“In the preclinical studies, we have obtained preliminary proof of the efficacy and safety of GH35 in KRAS G12C mutated malignancies,” said Dr. Qinhui Song, Chief Medical Officer of Genhouse, “moving GH35 forward in human studies could help us better evaluate its clinical value. Until today, no KRAS G12C inhibitor has been approved in China yet. We hope GH35 could be accessible to KRAS G12C mutated cancer patients as soon as possible.”


“FPFD of GH35 is another critical milestone of Genhouse. This is our first time to initiate a clinical study,” said Dr. Kuifeng Wang, founder and Chief Executive Officer of Genhouse, “we have high expectation and confidence in the clinical value of GH35. Genhouse Bio will continuously devote to provide broader and better therapeutic options for global cancer patients.”


About KRAS

The ras gene is the first oncogene discovered in history, which is also the most commonly mutated gene in cancer—about 30% of tumors have ras mutations. KRAS is the predominant subtype of the RAS family; mutations in kras count for about 85% of all ras mutations. Although KRAS has been heavily studied for 40 years, the development of targeted therapies for KRAS is quite bumpy, which granted KRAS the name of “undruggable target”. Until recently, the study of KRAS G12C mutants have made breakthrough progress, which makes it possible to design small molecule therapeutics to target KRAS.


About Genhouse

Genhouse Bio is an innovative biotech company focusing on the development of global next-generation small molecule anti-cancer therapeutics, which has a clear focus on overcoming those “undruggable” target and original innovation. Genhouse is dedicated to establishing a specialized new drug development system, with a SAR research platform based on structural biology, a Drug Screening platform based on target research and a Druggability Evaluation platform including efficacy, metabolic and safety profile evaluation.


By virtue of these platforms, Genhouse has built a highly innovative anti-cancer pipeline and successfully out-licensed the ex-China right of its SHP2 inhibitor GH21 to HuYa Bioscience International, a global biotech company. Genhouse will continue to advance more innovative programs into global development.

Privacy Statement

Genhouse Bio (Suzhou) Ltd. (“Genhouse” or “We”) respects the privacy of visitors (“Users”) to our website (“Site”), so we have developed this website privacy statement (“Privacy Statement”). This Privacy Statement indicates what information we collect about you and how that information is used. We may update the content of the Privacy Statement and suggest reading it regularly when you visit our Site.

Personal Information Collected by Genhouse

When you visit the Site, usually we will not collect any personal information from you. We might track your DNS and analyze the data to obtain understanding on visit trends. However, your identity will always remain anonymous, unless you specifically and knowingly provide it to us. When you provide such information, we will collect your personal information, such as when you contact us through the phone number or email address posted on the Site. But no matter when and how we collect your personal information, we will always provide link to this Privacy Statement. By willingly providing your personal information to us, you make the consent that we could use the information collected according to this Privacy Statement and admit that the information will be transferred from your locale to our office or server.

Information Disclosures and Sharing

Except as provided below, we will not share or sell your Personal Information with third parties unless otherwise stated by this Privacy Statement.

We might share your information according to this Privacy Statement, with Related Party who have consented to follow this Privacy Statement. Your personal information might also be transferred to other Related Party who represents us for purpose stated when we collect those information or other purposes permitted by law, such as Site evaluation, data management or technical support.

We might sell or buy business or assets during our operation. If Genhouse is acquired, merged, reorganized or dissolved or other alike situations happened, personal information might be part of the assets transferred. We may share personal information to respond to duly authorized subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law.


We might put a digital tag (more precisely “cookies”) on your hard disk driver for the server to recognize your computer and track usage information. Cookies will not reveal your personal information and you could always stay anonymous to us. The information we collected from Cookies will only be used for internal purpose and improve the service we provided to you through the Site. Users of our Site always have the option of disabling cookies via their browser preferences. If under any circumstances we collected your personal information, we will always inform you with your planned usage, contact and any Third Party that might get this information. All your personal information will maintain secrecy.

Links to Other Websites

If you apply to a job through our Site, you might be directed to other websites operated by Third Party. This Privacy Statement does not extend to any of these websites. Genhouse will not be responsible for any personal information collected by these websites operated by Third Party. Therefore, for any cases that a Third Party collect or use your personal information, Genhouse will not be legally responsible. We advise you to contact those websites directly and get their policies on personal information collection, safety, sharing and disclosure.

Contact Information

If you have any questions about our Privacy Statement, please do not hesitate to contact us at [].

Effective and Last Updated: April 15th 2021